Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments

Inclusion Criteria: * recurrent cancer refractory to available systemic therapy * 18 years old or older * predicted life expectancy equal or greater to 8 weeks * at least 4 weeks post chemotherapy, immunotherapy, surgery, or radiation therapy and have recovered from treatment toxicities * Karnofsky Performance Status equal or greater to 60 or ECOG equal or less than 2 * adequate organ function based on hematological, liver, and renal function * LVEF greater than the lower limit of normal for the institution, as measured by MUGA or by echocardiography * wash-out period before first dose os study drug if a protocol prohibited medication is being discontinued Exclusion Criteria: * pregnant or breastfeeding * received any other anti-cancer treatment or investigational therapy within 28 days prior to Cycle 1 Day 1 * symptoms of heart failure equal or greater to Class III (by NYHA criteria) * impaired cardiac function or clinically significant cardiac diseases * concurrent treatment with medications that either markedly induce or inhibit CYP3A4 * concurrent treatment with medications that have a relative risk of prolonging the QT interval or inducing torsades de pointes if treatment cannot be discontinued or switched to a different medication prior to study drug